This is a preview of subscription content, log in via an institution to check access.
References
Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105–123
Hashimoto K (2014a) R-Stereoisomer of ketamine as alternative of ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72–73
Hashimoto K (2014b) Targeting of NMDA receptors in the new treatment of schizophrenia. Expert Opin Ther Targets 18:1049–1063
Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of d-serine in patients with schizophrenia. Evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572–576
Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377
Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316
Hirabayashi Y, Furuya S (2008) Roles of l-serine and sphingolipid synthesis in brain development and neuronal survival. Prog Lipid Res 47:188–203
Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141
Maekawa T, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, Ohba H, Hattori E, Yamada K, Yoshikawa T (2010) Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of Shmt1 (SHMT1) in mice and schizophrenia. J Neurochem 115:1374–1385
Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Carcia A, Bernier M, Torjman MC, Barbas C, Zarate CA, Wainer JW (2014) d-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with major depressive disorder. Psychopharmacology in press
Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol Psychiatry 57:1493–1503
Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231:2041–2042
Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338
Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141
Acknowledgments
This study was supported by a Grant-in-Aid for Scientific Research on Innovative Areas of the Ministry of Education, Culture, Sports, Science, and Technology, Japan (to K. H.).
Conflict of interest
Dr. Hashimoto is an inventor on a filed patent application (pending) on “d-Serine as a biomarker of schizophrenia” and “The use of R-ketamine in the treatment of psychiatric diseases.” Dr. Hashimoto has served as a scientific consultant to Astellas and Taisho, and he also received the research support from Abbvie, Dainippon Sumitomo, Mochida, Otsuka, and Taisho.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hashimoto, K. Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology 231, 4081–4082 (2014). https://doi.org/10.1007/s00213-014-3735-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-014-3735-7